From Clinical Analytics Platform TriNetX Raises $40M to Speed Drug Trials:

Gadi Lachman, TriNetX CEO

Gadi Lachman, TriNetX CEO—

Courtesy photo

Underwriters and Partners

Xconomy Insight

Sponsored · Webinar
Sept. 15 – Challenges of Implementing Innovation in Drug Discovery & Development
Phenotypic Screening & Profiling to Understand a Compound's Disease Impact
Eurofins Discovery

Sponsored · Whitepaper
Potency Assay Development for Cell and Gene Therapy Products
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Absorption Systems

Sponsored · Webinar
Nov. 12 – High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived Cardiomyocytes
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX

Xconomy on Demand

We offer a number of ways to subscribe for free!